Financials data is unavailable for this security.
View more
Year on year Lyell Immunopharma Inc 's revenues fell -99.85% from 84.68m to 130.00k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 183.12m to a larger loss of 234.63m.
Gross margin | -- |
---|---|
Net profit margin | -389,368.50% |
Operating margin | -441,946.30% |
Return on assets | -28.23% |
---|---|
Return on equity | -32.26% |
Return on investment | -29.53% |
More ▼
Cash flow in USDView more
In 2023, Lyell Immunopharma Inc increased its cash reserves by 17.84%, or 22.10m. Cash Flow from Investing totalled 184.05m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 163.69m for operations while cash generated from financing totalled 1.74m.
Cash flow per share | -0.7504 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.21 |
---|---|
Tangible book value per share | 2.21 |
More ▼
Balance sheet in USDView more
Current ratio | 16.19 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼